Skip to content

爱普塔集团

US · ATR #1713 按市值排名 上市于 1970
124.51 +0.25 +0.20%
实时 - 追踪5344个代码 - 心跳于116秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

低于合理价值
144.47 合理价值 ≈ 171.85 199.24
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为144.47-199.24。
  • 当前价格比按平均倍数计算的合理价值(171.85)低27.5%。

估值 各估值倍数与自身5年区间的对比

市净率 2.90 低于历史水平 第5百分位
5年平均 3.70 · 在Medical Instruments & Supplies中排名第25/51
市盈率 21.63 低于历史水平 第11百分位
5年平均 29.18 · 前瞻 20.35 · 在Medical Instruments & Supplies中排名第8/27
市销率 1.94 低于历史水平 第4百分位
5年平均 2.43 · 前瞻 1.89 · 在Medical Instruments & Supplies中排名第19/51

同业对比 Medical Instruments & Supplies

公司 市值 市盈率(TTM) 市净率 股息率
爱普塔集团 (ATR) 7.92B 22.47 3.01 1.52%
Intuitive Surgical (ISRG) 150.74B 48.93 8.30 0.00%
Becton Dickinson & Co (BDX) 52.23B 57.93 2.14 2.19%
ResMed (RMD) 33.61B 22.91 5.10 1.00%
Alcon (ALC) 31.99B 50.52 1.48 0.53%
Medline (MDLN) 31.55B 68.24 2.73 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值144.56 经济护城河Narrow 不确定性Low

当前股价低于晨星合理价值估算16.1%。

合理价值

AptarGroup Inc is assigned a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 17% discount to our quantitative fair value estimate of $144.56 per share, which is reinforced by this estimate's low uncertainty rating.

The company's profitability strengthens our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's enterprise value to free cash flow ratio of 18.4 lies in the bottom 40% globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be cheap.

On a different note, the company's balance sheet is potentially concerning. Excessive leverage heightens financial risk, potentially undermining a firm's value. The firm's EBITDA/interest coverage ratio of 12.8, for example, ranks in the bottom 50% globally. This gives us pause, as it can be a warning sign of financial distress if conditions don't improve. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

经济护城河

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

爱普塔集团 讨论区 0 条评论

发表评论